Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL. - Srinagesh HK; Gupta V; Zhang A; Grunwald M; Connor M; Kota VK; Boccucci J; Ulrickson M; Pradeep R; Hill L; Tsai SB; O'Connor T; et al. (Blood, 2026)